Pulmonary Cryptococcosis After Initiation of Anti-Tumor Necrosis Factor-α Therapy
Authors:
- Karen L. WoodKWKaren L. Wood
- Helen T. Winer-MuramHWHelen T. Winer-Muram
- Stephen J. WilsonSWStephen J. Wilson
- George SarosiGSGeorge Sarosi
- Kenneth S. KnoxKKKenneth S. Knox
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Effects of Tumor Necrosis Factor Alpha on Dendritic Cell Accumulation in Lymph Nodes Draining the Immunization Site and the Impact on the Anticryptococcal Cell-Mediated Immune ResponseInfection and Immunity, 2003
- Induction of Interleukin-12 and Gamma Interferon Requires Tumor Necrosis Factor Alpha for Protective T1-Cell-Mediated Immunity to PulmonaryCryptococcus neoformansInfectionInfection and Immunity, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Role of TNF-α in the Induction of Fungicidal Activity of Mouse Peritoneal Exudate Cells againstCryptococcus neoformansby IL-12 and IL-18Cellular Immunology, 1999
- Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformansThe Journal of Immunology, 1996
- The Evolution of Pulmonary CryptococcosisAnnals of Internal Medicine, 1981